UBS has reiterated its "Buy" rating for Symrise, with a target price of 139 euros.
According to analyst Charles Eden, the target for organic sales growth has been raised, although there was a decline in organic growth reported in the third quarter, which is believed to be due to heightened investor expectations following a strong performance by competitor Givaudan.
Eden suggested that investors may have considered an 11 percent sales increase to be a more realistic benchmark based on recent comparative figures.
The report, published on October 24, 2024, at 06:30 GMT, reflects UBS's continued confidence in Symrise despite the challenges of meeting high market expectations.